Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.

Journal of clinical pharmacology - 1 Apr 2014

Ribas Antoni, Zhang Weijiang, Chang Ilsung, Shirai Keisuke, Ernstoff Marc S, Daud Adil, Cowey C Lance, Daniels Gregory, Seja Elizabeth, O'Laco Elizabeth, Glaspy John A, Chmielowski Bartosz, Hill Todd, Joe Andrew K, Grippo Joseph F

Abstract excerpt

Vemurafenib is an orally bioavailable BRAF inhibitor approved for the treatment of BRAF(V600) -mutant metastatic melanoma. It is important to understand the effects of a high-fat meal on the pharmacokinetics (PK) of vemurafenib in humans because it is a Biopharmaceutics Classification System Clas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dietary Fats

Share to Indoles

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 24374975
DOI: 10.1002/jcph.255

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24374975-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.PMID 24374975Read ↗

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.Semantic proximity Read ↗

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.Semantic proximity Read ↗

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies.Semantic proximity Read ↗

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies.Semantic proximity Read ↗

Predicting the Influence of Fat Food Intake on the Absorption and Systemic Exposure of Small Drugs using ANDROMEDA by Prosilico SoftwareSemantic proximity Read ↗

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.Semantic proximity Read ↗

Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.Semantic proximity Read ↗

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.